Impact of Steroids on Inflammatory Response in Covid-19

• Status: Completed
• Trial end date: 2021-08-20
• Target enrollment: 0
• Participant gender: All

Summary

we designed this study to observe the efficacy and safety of dexamethasone versus methylprednisolone in covid-19 diseased patients upon monitoring the inflammatory response and to compare the outcome when these steroids will be given in covid-19 diseased patients in our ICU.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Assiut University
• Treatments: Dexamethasone; Methylprednisolone; Methylprednisolone Acetate; Methylprednisolone Hemisuccinate; Prednisolone; Prednisolone acetate; Prednisolone hemisuccinate; Prednisolone phosphate

Criteria

Inclusion Criteria:

• Adults (age 18-no limit years) who will be diagnosed covid-19

• With destructive inflammatory immune response needing ICU admission to be run on steroid therapy.

Exclusion Criteria:

• Severe immunosuppression like HIV (Human immunodeficiency Virus)

• Long term use of immunosuppressant for any other chronic illness

• Pregnant or lactating females

• Patients who are on chronic use of corticosteroids like asthma, rheumatoid arthritis.